Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Assets (2020 - 2025)

Maxcyte (MXCT) has disclosed Current Assets for 6 consecutive years, with $118.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 31.05% to $118.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.4 million through Dec 2025, down 31.05% year-over-year, with the annual reading at $118.4 million for FY2025, 31.05% down from the prior year.
  • Current Assets for Q4 2025 was $118.4 million at Maxcyte, down from $124.6 million in the prior quarter.
  • The five-year high for Current Assets was $270.4 million in Q4 2021, with the low at $84.6 million in Q2 2021.
  • Average Current Assets over 5 years is $199.0 million, with a median of $190.2 million recorded in 2023.
  • The sharpest move saw Current Assets surged 497.6% in 2021, then plummeted 31.05% in 2025.
  • Over 5 years, Current Assets stood at $270.4 million in 2021, then fell by 6.72% to $252.3 million in 2022, then decreased by 24.61% to $190.2 million in 2023, then dropped by 9.73% to $171.7 million in 2024, then tumbled by 31.05% to $118.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $118.4 million, $124.6 million, and $143.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.